-

Dexcom Launches Its First Open Call to Uncover the Next Diabetes Advocates Ahead of World Diabetes Day

  • Now through Sept. 19, people in the U.S. and Canada from 2 years and older living with all types of diabetes and prediabetes can apply for a once-in-a-lifetime opportunity to raise diabetes awareness on a global scale.
  • Selected candidates will be given a global platform to champion the diabetes community while starring in Dexcom’s 2025 World Diabetes Day campaign.

SAN DIEGO & BURNABY, British Columbia--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of its first open call in the U.S. and Canada in search of the next diabetes advocates. Those selected will experience a once-in-a-lifetime opportunity to raise awareness and share their voice on a global scale this World Diabetes Day (Nov. 14) and beyond.

Now through Sept. 19, people from 2 years and older living with all types of diabetes and prediabetes – including Dexcom Warriors* and Stelo ambassadors† – can apply at Dexcom.com/WorldDiabetesDay. Those selected will embody strength, advocacy and pride living with diabetes.

“We’ve long believed that real people with diabetes should be the voice of our company, and we’ve fostered that belief through our global Dexcom Warrior and Stelo Ambassador communities,” said Anne Santoro, senior vice president, product marketing at Dexcom. “Now, we’re giving these communities – and anyone living with diabetes who’s passionate about raising awareness – a chance to share their voice on a global stage.”

Those selected will receive an invite to participate in a photoshoot in Los Angeles to have their unique and inspiring story featured in Dexcom’s 2025 World Diabetes Day campaign. They’ll also have ongoing support from Dexcom over the next year to attend events, connect with the diabetes community and continue to advocate for diabetes awareness.

“I never sought to be the face of diabetes advocacy – I just wanted to share my story and hope that it would connect with people,” said Nick Jonas, American multi-platinum recording artist, songwriter, actor and philanthropist. “Over the years, I’ve learned that using our voices to spread messages of support, hope and perseverance can have a major impact on people’s lives, so I’m proud to support this open call and see Dexcom empower people with diabetes to do even more incredible work in their communities.”

To nominate yourself or someone you know, visit Dexcom.com/WorldDiabetesDay. Nominations close Sept. 19 at 12 p.m. PDT.

About Dexcom

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

Dexcom. Discover what you’re made of. For more information, visit www.dexcom.com.

*

Dexcom G-Series products are indicated for individuals with T1, T2 or Gestational Diabetes ages 2 years and older

†

Stelo is cleared by the FDA for adults not on insulin who are 18 or older* in the United States

 

Contacts

Media Contact
James McIntosh
mediarelations@dexcom.com

Investor Contact
Sean Christensen
sean.christensen@dexcom.com

DexCom, Inc.

NASDAQ:DXCM

Release Versions

Contacts

Media Contact
James McIntosh
mediarelations@dexcom.com

Investor Contact
Sean Christensen
sean.christensen@dexcom.com

More News From DexCom, Inc.

Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the significant benefits of continuous glucose monitoring (CGM) for adults with Type 2 diabetes not on insulin. CONNECT participants using Dexcom G7 experienced an average 1.6% A1C reduction from a mean baseline of 8.8%,...

Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2026 financial results after market close on Thursday, October 29, 2026. Management will hold a conference call to review the company's third quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will...

Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading

SAN DIEGO--(BUSINESS WIRE)--DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the company’s one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.Now in its fifth year, this marks the program’s largest and most expansive roster to date, featuring 27 college athletes, 12 new and 15 returning, across 13 sports. The expansion is backed by new research showing that programs l...
Back to Newsroom